Caspofungin study enrollment criteria
Author:
Maertens J, Raad I, Sable CA, Ngai A, Berman R, Patterson TF, Denning DW, Walsh T.
Date: 1 September 2002
Abstract:
noncomparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to amphotericin B (AMB), AMB lipid formulations (lipid AMB), or azoles. Interscience Conference on Antimicrobial Agents and Chemotherapy.
Download the full article (Disclaimer)
This manuscript library of ~16,000 articles (1729-2024) related to Aspergillus and aspergillosis is intended for individual study only, and is provided as contribution to global understanding of the topic. Please refer to the publisher’s guidance about any other usage.